amigos@masc.org.au
AMIGOs
  • Merkel Cell Carcinoma
    • About MCC
    • Diagnosis
    • Treatment
    • Staging
  • Research
  • Patient Stories
  • Support
    • Referral
    • Patient Advocacy Group
    • Resources
  • Communications
    • Events
    • Publications
  • About Us
Select Page

Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic MCC progressed on chemotherapy

by MASC-Admin | Jul 11, 2018 | Current News

Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic MCC progressed on chemotherapy;Paul Nghiem et al. At the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr Paul Nghiem (University...

Durable tumor regression and OS in patients with advanced MCC receiving pembrolizumab as first-line therapy

by MASC-Admin | Jul 11, 2018 | Current News

Durable tumor regression and OS in patients with advanced MCC receiving pembrolizumab as first-line therapy;Paul Nghiem et al. At the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr Paul Nghiem (University of Washington) presented data on patients...
Next Entries »

Recent Posts

  • The changing paradigm of managing Merkel Cell Carcinoma in Australia: An expert commentary
  • Treatment of primary Merkel cell carcinoma: Radiotherapy can be an effective, less morbid alternative to surgery
  • NCCN Guidelines as published in JNCCN
  • The first-ever
  • ADAM trial:

Recent Comments

    Archives

    • September 2020
    • July 2020
    • July 2018
    • April 2018

    Categories

    • Current News

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org